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was achieved in 4 patients. No surgery-related mortality 
or signifi cant morbidity was reported. Adjuvant radio-
therapy was delivered in 15 patients, and 30 patients re-
ceived defi nitive radiotherapy.  Conclusion: In the pres-
ent study, the combination of paclitaxel, carboplatin and 
gemcitabine has been a safe and active regimen in poor-
prognosis stage IIIA N2 bulky NSCLC. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 Lung cancer is the leading cause of death worldwide 
 [1] . Non-small cell lung cancer (NSCLC) is locally ad-
vanced stage III in one third of patients at diagnosis. Sin-
gle modality therapy, with either surgery or radiotherapy 
alone, is curative for only a small minority of patients who 
present stage III. After initial therapy, a majority of pa-
tients suffers disease recurrence. Relapses are local in one 
third and distant in two third of patients. Therefore, one 
important stage of the therapeutic strategy is the use of 
chemotherapy in addition to local treatment in the man-
agement of locally advanced NSCLC. A number of phase 
II–III trials have investigated the use of induction chemo-
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 Abstract 
 Background: Induction chemotherapy followed by surgi-
cal resection or defi nitive radiotherapy for patients af-
fected by stage IIIA N2 bulky non-small cell lung cancer 
(NSCLC) has been investigated in several trials.  Patients 
and Methods: In this present study, 52 patients with 
stage IIIA N2 bulky NSCLC with cytologically or histo-
logically confi rmed mediastinal lymph node involve-
ment received paclitaxel 175 mg/mq on day 1, carbopla-
tin AUC 5 on day 1 and gemcitabine 1,000 mg/mq on
day 1 and 8 every 3 weeks for three cycles as induction 
chemotherapy.  Results: Objective response (4 complete 
remission and 36 partial remission) was achieved in 
40/52 patients. No early or toxic deaths were observed. 
Twenty-two patients were surgically explored. Fifteen 
were excluded for resection for biopsy-proven residual 
tumour in mediastinal nodes. Complete surgical resec-
tion was performed in 15 patients with confi rmed patho-
logical downstaging. Pathological complete response 
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therapy followed by surgical resection in patients with N2 
disease  [2–9] . The data from these studies support the role 
of pre-operative chemotherapy in improving resectability 
and survival over surgery in stage IIIA N2. 
 The combination of paclitaxel and carboplatin is actu-
ally one of the common regimes used as induction che-
motherapy for NSCLC. New triplet chemotherapy com-
binations are under investigation. The present study was 
designed to assess the efﬁ cacy and safety proﬁ le of pacli-
taxel, carboplatin and gemcitabine combination as induc-
tion chemotherapy for stage IIIA N2 bulky NSCLC. The 
primary endpoint of this study was objective radiological 
response. Secondary endpoints were survival, toxicity 
and safety of chemotherapy. 
 Patients and Methods 
 Patient Eligibility 
 Eligibility criteria were clinical stage IIIA NSCLC with patho-
logically documented N2 and locally unresectable disease. Medias-
tinal lymph nodes  1 2.0 cm in short-axis diameter at CT scan and 
measurable disease were required, as well as an age between 18 and 
75 years and an Eastern Cooperative Oncology Group (ECOG) 
performance status  ^  2. Preserved haematologic and renal func-
tions were also required. No previous cancer, arrhythmias or car-
diac insufﬁ ciency  1 2 (New York Heart Association Scale) were 
admitted. 
 Further exclusion criteria were pregnancy and inadequate con-
traceptive precautions. All patients were required to provide writ-
ten informed consent prior to initiation of treatment. 
 Study Design 
 This study was designed according to Simon’s two-stage design 
 [10] . The primary aim was to assess the efﬁ cacy of paclitaxel, car-
boplatin and gemcitabine combination as induction treatment for 
patients with stage IIIA N2 bulky NSCLC. If the response rate was 
 6 50%, this induction chemotherapy was used in further patients. 
Baseline evaluation included complete history and physical exam-
ination, CT scan of brain, chest and upper abdomen, radionuclide 
bone scan, ﬁ bre-optic bronchoscopy with bronchoaspirate and/or 
brushing and/or bronchial biopsy, complete blood cell count and 
serum chemistry analysis. Transbronchial needle aspiration 
(TBNA) and/or mediastinoscopy was routinely performed. All pre-
treatment imaging procedures were performed within 4 weeks from 
study entry. Tumour response was assessed with CT scan after three 
cycles according to WHO criteria. TBNA or mediastinoscopy was 
repeated in patients with no progressive disease, since chest CT 
scan is not accurate enough to predict pathological response in me-
diastinal lymph nodes. Patients without pathologically document-
ed residual mediastinal disease were eligible for surgery. On the 
contrary, patients with pathologically (mediastinoscopy/TBNA/
thoracotomy) documented disease in the mediastinal nodes re-
ceived deﬁ nitive radiotherapy. The combined modality therapy of 
this study (chemotherapy and surgery and/or radiotherapy) did not 
allow the formal 4-week conﬁ rmation of response to chemotherapy. 
Positron emission tomography was permitted, but not routinely 
performed. All toxicities were coded according to the National Can-
cer Institute Bethesda Common Toxicity Criteria  [11] . The overall 
survival was estimated using the Kaplan-Meier technique  [12] . 
 Treatment 
 Patients received paclitaxel 175 mg/mq on day 1, the carbopla-
tin AUC 5 on day 1 and gemcitabine 1,000 mg/mq on day 1 and 8, 
every 3 weeks for three cycles. Paclitaxel infusion preceded carbo-
platin. Gemcitabine was infused after carboplatin infusion on 
day 1. All patients were pre-medicated with dexamethasone 8 mg 
given as an intravenous injection, chlorpheniramine 10 mg as in-
tra-muscular injection and ranitidine 50 mg, intravenously. A com-
bination of HT 3  antagonist and dexamethasone was administered 
to day 3 to prevent nausea and vomiting. 
 Treatment was repeated every 3 weeks if the neutrophil count 
was above 1,500/ml and platelets  1 100,000/ml. For patients who 
experienced drug toxicity, the dose for subsequent cycles was mod-
iﬁ ed as outlined in  table 1 . After one episode of grade 4 neutropenia 
or febrile neutropenia, prophylaxis with recombinant human gran-
ulocyte colony-stimulating factors was administered. After grade 
3–4 non-haematological toxicity, excluding hair loss, therapy was 
delayed until recovery. The use of recombinant erythropoietin was 
left to the individual decision of the physician. Within cycles,
doses of gemcitabine on day 8 were modiﬁ ed as follows: no reduc-
tion for neutrophils  1 1,500/ml and platelets  1 100,000/ml; 25% 
dose reduction for neutrophils 1,000–1,500/ml and/or platelets 
75,000–100,000/ml; no administration for neutrophils  ! 1,000/ml 
and/or platelets  ! 75,000/ml. Three cycles of chemotherapy were 
administered unless progressive disease or intolerable toxicity was 
registered. 
 Results 
 Efﬁ cacy 
 A total of 52 patients were enrolled from December 
1999 to February 2004 ( table 2 ). All patients were assess-
able for response and toxicity. The overall response rate 
was 70% in the interim analysis which was performed in 
May 2002 after the ﬁ rst 20 enrolled patients. Of the 52 
evaluable patients, 40 responded, showing an overall re-
sponse rate of 77% (95% CI 52–90%). Complete remis-
sion (CR) was achieved in 4 patients. Partial remission 
(PR) was observed in 36 patients. Stable disease (SD) was 
observed in 5 patients and progressive disease (PD) in 7. 
Repeated mediastinoscopy or TBNA was required in 15 
patients. 
 Twenty-two patients were considered eligible for radi-
cal surgery after induction chemotherapy. At the present 
time, 17 patients were submitted to surgery with con-
ﬁ rmed pathological downstaging. Five were excluded for 
biopsy-proven residual tumour in mediastinal nodes at 
thoracotomy. Lobectomy was performed in 15 cases, 
while pneumonectomy was only performed in 2 patients. 
Resections were considered complete in 15 patients. Four 
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patients achieved pathological complete response (pCR). 
Patients who achieved a pCR were those having a major 
radiographic response. No surgery-related mortality was 
reported and no signiﬁ cant morbidity was observed dur-
ing the 30 post-operative days. At a median follow-up of 
26 months, the median duration of survival was 22 
months (95% CI 16.9–32.1 months). Fifteen patients re-
ceived adjuvant radiotherapy. Deﬁ nitive radiotherapy 
(65 Gy) was given to 30 patients (23 with PR, 5 with SD 
and 2 with locoregional PD) with persistent mediastinal 
disease after induction chemotherapy. For these patients, 
the overall response was 83% after sequential chemora-
diotherapy and the median overall survival was 20 months 
(95% CI 15.9–31.1 months). Among the 15 completely 
resected patients, 3 had disease recurrence 9–12 months 
after surgery. 
 Toxicity 
 The highest toxicity was a haematological one, with 
neutropenia as the major side effect. Only 2 patients had 
febrile neutropenia. Other less frequent high-grade tox-
icities included nausea-emesis, neuropathy, muscle pain, 
asthenia, diarrhoea and liver toxicity ( table 3 ). Grade 3 
Blood cells Nadir Dose (ﬁ rst episode, 
all three drugs), %
Dose (second episode, 
all three drugs), %
Haematological toxicity
PMN <1,000–1,500/ml 100 100
PMN 500–1,000/ml 100 100
PMN <500/ml 75a 75a
Platelets 75–100,000/ml 100 100
Platelets 50–75,000/ml 100 100
Platelets 25–50,000/ml 75 50
Platelets <25,000/ml 50 Withdraw
Non-haematological toxicityb
Grade 1–2 100 100
Grade 3 75 50
Grade 4 50 Withdraw
PMN = Polymorphonuclear neutrophil.
a + Recombinant human granulocyte colony-stimulating factor.
b For hepatic toxicity grade 3: withdrawal of gemcitabine after the second episode.
Table 1. Dose modiﬁ cation protocol for 
treatment
Table 2. Patient demographics and baseline 
disease characteristics
Total patients 52
Age, years
Median 64
Range 34–75
Sex
Male 40
Female 12
ECOG performance status
0 33
1 18
2 1
Histology
Squamous cell 20
Adenocarcinoma 29
Large cell 3
Stage
T2N2 20
T3N2 32
Table 3. High-grade toxicities (n = 52)
Toxicity Grade 3 Grade 4
Neutropenia 26 11
Febrile neutropenia 2 0
Anemia 5 1
Thrombocytopenia 12 1
Neuropathy 2 0
Nausea/vomiting 5 0
Diarrhoea 1 0
Elevation of transaminases 3 1
Muscle pain 6 0
Asthenia 15 0
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elevation of transaminases was observed in 3 patients, 
but it was reversible. There were no early or toxic deaths. 
All patients received all three cycles of induction chemo-
therapy. The median delivered relative dose intensity was 
84% for paclitaxel (range 75–102), 84% for carboplatin 
(range 75–105) and 82% for gemcitabine (range 50–
102.5) 
 Discussion 
 Combined modality therapy involving a combination 
of chemotherapy and local treatment has improved out-
comes for patients with stage III NSCLC: a 5-year sur-
vival of 25 and 15% in stages IIIA and IIIB can be ex-
pected. Stage IIIA, including tumours with ipsilateral me-
diastinal node involvement (T1–3N2), represents the 
most controversial subset of lung cancer patients because 
of the heterogeneity in clinical presentation, treatment 
and prognosis. 
 Despite a negative pre-operative staging including CT 
scan, positron emission tomography and mediastinosco-
py, mediastinal lymph node metastases after thoracoto-
my (incidental N2) were found in some patients. Nodal 
disease was found at the ﬁ nal pathological examination 
of surgical specimen or intra-operatively as an unexpect-
ed ﬁ nding with frozen section pathologic examination of 
mediastinal nodes. However, a majority of patients with 
stage IIIA have enlarged ( 1 1 cm in short-axis diameter) 
N2 nodes at CT scan. In this setting, mediastinoscopy was 
generally performed, since approximately 40% of moder-
ately enlarged nodes are benign. To optimize the chance 
for cure, patients with pre-operatively documented N2 
and potentially resectable disease should receive induc-
tion chemotherapy followed by surgery. Theoretical ad-
vantages of induction chemotherapy include decreasing 
tumour size to allow more ready resection and decreased 
micrometastases and surgical seeding. In stage IIIA, pre-
operative phase II chemotherapy studies have shown im-
proved outcome compared with historical controls. These 
studies showed a response rate of 64–77%, with 15–74% 
of complete resections and 0–18% treatment-related 
deaths. These results have been validated by three small 
randomized phase III studies  [5–7] which, however, can 
be criticized on several points: no pathological staging of 
mediastinal nodes, inclusion of patients with inhomoge-
neous prognosis (T3 N0–1, bulky N2 or stage IIIB) and 
small samples. Furthermore, these results were not con-
ﬁ rmed by other studies  [13–16] and overall survival was 
not reported in two studies  [13, 14] . No signiﬁ cant sur-
vival beneﬁ t for induction chemotherapy was achieved 
in two studies  [15, 16] . At last, treatment-related mortal-
ity is high in some trials. However, for many patients with 
bulky N2 disease, the role of surgery is questionable. 
 These patients may be suitable for combined modality 
treatment with chemotherapy and radiotherapy, as sev-
eral trials of induction chemotherapy followed by radio-
therapy and of chemotherapy delivered concomitantly 
with radiotherapy have shown improved survival over 
deﬁ nitive radiotherapy alone. Furthermore, three meta-
analyses of trials comparing radiotherapy alone with cis-
platin-based chemoradiation for locoregional disease 
have conﬁ rmed the survival beneﬁ t of combined modal-
ity therapy  [17–19] . There have been trials of cisplatin-
based sequential chemoradiation which have shown an 
advantage over combined modality therapy in patients 
with unresectable locoregional disease. In the ﬁ rst trial of 
Dillman et al.  [20] addressing this issue, the objective tu-
mour response rate was improved with chemoradiation 
as compared with radiotherapy alone (56 vs. 43%). Ad-
ditionally, a survival advantage over combination thera-
py was detected (5-year overall survival 13 vs. 6%). A 
trial by the Radiation Therapy Oncology Group  [21] and 
a trial from France  [22] also showed a survival beneﬁ t of 
the use of sequential chemoradiotherapy. 
 These patients may be suitable for sequential radio-
therapy as the disease is considered unresectable. Thera-
peutic strategy is complicated by the lack of a clear deﬁ -
nition of what constitutes ‘bulky N2’ and/or ‘unresect-
able’ disease. The deﬁ nition of ‘resectable’, ‘marginally 
resectable’ or ‘unresectable’ is not clear as it is subjective 
and highly dependent on the experience and expertise of 
the thoracic surgeon, as is the deﬁ nition of bulky N2 dis-
ease. In this present study, bulky N2 disease is deﬁ ned as 
involving mediastinal nodes  1 2 cm in short-axis diameter 
in CT scan. 
 Furthermore, since clinical restaging after induction 
chemotherapy with chest CT scans and/or positron emis-
sion tomography is not accurate to predict pathological 
response in mediastinal lymph nodes, repeated mediasti-
noscopy or TBNA was required in some patients. Patients 
with pathologically documented residual mediastinal dis-
ease were excluded from surgery and received deﬁ nitive 
radiotherapy. Patients without mediastinal disease were 
submitted to surgery. In this present phase II study, the 
combination of paclitaxel, carboplatin and gemcitabine 
showed promising anti-tumoral activity and was well tol-
erated in combined modality therapy of stage IIIA N2 
bulky NSCLC, with cytological or histological conﬁ rma-
tion of lymph node involvement. Objective response was 
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achieved in 40/52 patients. Mediastinoscopy or TBNA 
was repeated after induction chemotherapy in some pa-
tients. After induction chemotherapy, 22 patients were 
considered eligible for radical surgery. Patients with 
pathologically documented residual mediastinal tumour 
were excluded for surgery. Seventeen patients were sub-
jected to radical surgery with conﬁ rmed pathological 
downstaging. Resections were considered complete in 15 
patients. pCR was observed in 4 patients. No surgery-re-
lated mortality or signiﬁ cant morbidity was observed. 
The use of induction chemotherapy appeared safe and 
did not increase surgical complications. At a median fol-
low-up of 26 months, the median overall survival was 22 
months. Thirty patients with persistent mediastinal dis-
ease after induction chemotherapy received deﬁ nitive ra-
diotherapy. For these patients (23 with RP, 5 with SD 
and 2 with locoregional PD after induction chemothera-
py), the overall response rate was 83% after sequential 
chemoradiotherapy and the median overall survival was 
20 months. These results are encouraging if compared 
with a number of trials using different platinum-based 
chemotherapy regimes followed by resection in stage 
IIIA. 
 In the largest published phase II trial, 136 patients with 
stage IIIA, with bulky or multilevel clinical N2, received 
two to three cycles of cisplatin-mitomycin and vinblastin 
or vindesine combination chemotherapy before explor-
atory surgery  [2] . Seventy-seven of these patients re-
sponded to neo-adjuvant chemotherapy, 72% were surgi-
cally explored and 84% of them underwent complete re-
section of tumour tissue. pCR was achieved in 19% of the 
patients. The median survival of all patients was 19 
months. In completely resected patients, median surviv-
al was 27 months. Survival was impressive ( 1 50% at 5 
years) in patients who achieved complete response to the 
induction chemotherapy. This highlights the importance 
of a pCR for long-term survival. However, in trials em-
ploying the combination of cisplatin, vinca-alkaloid and 
mitomycin, a mortality of 18% was reported  [3] . Indeed, 
triple combination with ‘older drugs’ as induction chemo-
therapy may be associated with high treatment-related 
mortality. Newer generation chemotherapeutic agents 
are being incorporated into combined modality therapy 
for locally advanced NSCLC. The EORTC 09858 phase 
II study reported that carboplatin and taxol are an active 
induction regimen in biopsy-proven stage IIIA N2 bulky 
NSCLC  [23] . Of the 52 eligible patients, 33 responded (1 
CR and 32 PR) at an overall response rate of 64%. Me-
dian overall survival was 20.5 months. Grade 3–4 neu-
tropenia was reported in 63% of patients. A total of 35 
patients was randomized to additional surgery or radio-
therapy according to the protocol. From the 15 patients 
randomized in the surgery arm, 12 received surgery. Re-
section was considered complete in 2 of them. One pa-
tient died 5 days after surgery with pulmonary hyperten-
sion. Furthermore, a phase II trial of combined modality 
therapy, with carboplatin and paclitaxel concurrent with 
radiotherapy, yielded an overall response rate of 55% in 
38 valuable patients  [24] . Triple combination with car-
boplatin and new drugs gemcitabine and paclitaxel may 
be superior to paclitaxel and carboplatin alone as induc-
tion chemotherapy. Data from several studies  [25–27] 
have evaluated the addition of gemcitabine to paclitaxel 
plus carboplatin in advanced NSCLC. The response rates 
ranged from 21 to 61%. Only a mild increase in trombo-
cythopenia was observed as compared with paclitaxel and 
carboplatin alone. Preliminary results of randomized tri-
als in advanced NSCLC indicated an advantage for drug 
combination paclitaxel, carboplatin and gemcitabine as 
compared with paclitaxel and carboplatin alone  [23, 28, 
29] . In the present study, the combination of paclitaxel, 
carboplatin and gemcitabine is an active regimen in bulky 
N2 disease. Forty of the 52 eligible patients responded. 
Seventeen patients were submitted to surgery. Resection 
was considered complete in 15 of them. Additionally, 4 
patients achieved pCR. The studies conducted in N2 dis-
ease have pointed towards improved survival for those 
patients able to undergo a complete resection and for pa-
tients who achieved pCR after induction chemotherapy. 
In conclusion, this regimen is safe, and no treatment-re-
lated mortality or signiﬁ cant morbidity was reported. 
These results are encouraging. Phase III studies are cur-
rently underway to verify the role of induction chemo-
therapy and to assess the best chemotherapy to be used. 
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